AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$AMPH

Amphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soars

Amphastar Pharmaceuticals (AMPH) reported Q3 2026 revenue of $207.6M, up 8.2% YoY and 5.9% above estimates. Adjusted EPS of $1.14 beat estimates by 32.8%. Operating margin was 24.5%, in line with the prior year. The company cited strong sales of key products and pipeline advancements. Shares rose 7.2% post-results.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 10:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soars — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AMPHBullishHigh
01

Why it matters

The earnings surprise provides a fresh catalyst for short‑term buying, while margin pressure suggests caution on the upside.

02

Market read

First‑report earnings beat for a mid‑cap biotech creates immediate trading opportunity; broader market impact is limited.

03

What to watch

The company's share buyback activity and shrinking share count could support EPS growth beyond organic performance.

Relevance 8/10Novelty 9/10Timing: post‑market today

Background

Amphastar Pharmaceuticals reported Q3 2026 results that beat consensus estimates on both revenue and EPS, with the stock rallying 7% immediately after release.

Company-level read

Ticker impact

$AMPHBullishHigh confidence
Context

Q3 2026 revenue $207.6M beat estimates by 5.9% and adjusted EPS $1.14 beat by 32.8%, sending the stock up 7.2% after the release.

Expected impact

likely continued upside as investors price in the earnings beat, though margin pressure may cap gains.

Evidence & confidence

The surprise revenue and EPS beat provide fresh buying impetus; the 4‑point margin decline tempers enthusiasm but does not outweigh the beat.

Market effects

Sector

The beat highlights strength in the generic/ biosimilar segment, potentially lifting peers in the specialty pharma space.

Regional

Limited to U.S. small‑cap healthcare investors; no broad regional effect.

Global

Modest, as Amphastar is a niche player; impact confined to biotech/healthcare niche.

Counterpoint

What could challenge this read

Margin compression and slowing revenue growth over the past two years could signal a turning point; a pullback may follow the short‑term rally.

Key entities

  • Company
    Amphastar Pharmaceuticals

    U.S. listed specialty pharma firm (NASDAQ:AMPH) reporting Q3 2026 earnings.

Read at source← All news

StoryAmphastar posts Q3 2026 revenue of $207.6 million, GAAP profit of $37.8 million

Also covered by

5 outlets

Related articles

$AMPHHigh

Amphastar (AMPH) Q3 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q3 2026 revenue of $207.6M, up 8% YoY, driven by BAQSIMI and Primatene MIST sales. Gross margin fell to 48% due to pricing pressures and IMS facility remediation costs. EPS rose to $1.14. The company increased its share buyback program by $50M and expects high single-digit Q4 growth. IMS backlog stands at $12.5M due to operational constraints. Insulin aspart launch is targeted for 2027, pending FDA approval.

fool.com
$AMPHHighAI 8/10

Amphastar Pharmaceuticals Inc (AMPH) Q3 2026 Earnings Call Highlights: Record Revenue

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M, up 8% YoY, with adjusted EPS of $1.14. CFO Bill Peters addressed pricing headwinds, IMS remediation costs, and growth drivers like Baximi and Primatene Mist. The company expects continued lidocaine demand but constrained capacity. Insulin biosimilar launches are planned for 2027, with margin normalization dependent on higher volumes. Q4 sales are expected to grow in the high single digits.

finance.yahoo.com
$AMPHMed

Amphastar Pharmaceuticals Q3 Earnings Call Highlights

Amphastar Pharmaceuticals reported Q3 gross margin decline to 48% from 51% YoY, citing lower pricing for BAQSIMI and increased manufacturing costs. The company expects higher remediation expenses in coming quarters. Amphastar aims to reduce a $12.5M backlog and sees continued lidocaine demand. It remains on track for potential 2027 launches of insulin aspart biosimilar and AMP-018, with other pipeline updates. Operating cash flow was $43.3M, and the board authorized $50M for share repurchases.

finance.yahoo.com
$AMPHHigh

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 ​ - Net revenues of $207.6 million for the three months ended September 30, 2026 ​ - GAAP net income of $37.8 million, or $0.87 per share, for the third quarter ​ - Ad

SEC EDGAR 8-K